Kane Biotech Inc. (TSX-V:KNE) has completed a private placement offering of 14,000,000 common shares at $0.05 per share, raising $700,000 for working capital and general corporate purposes. The offering is subject to a hold period of four months and one day, with final approval pending from the TSX Venture Exchange. This transaction is considered a “related party transaction” under Multilateral Instrument 61-101. The securities offered have not been registered under the United States Securities Act of 1933 and may not be sold in the U.S. More information can be found on Kane Biotech’s website.

Read more at GlobeNewswire: Kane Biotech Announces Closing of Private Placement